Category: News

Interview: BUHLMANN fCAL ELISA in a Clinical Laboratory- Expert User Perspectives

BÜHLMANN fCAL® ELISA is FDA 510(k) cleared.  For in vitro Diagnostic Use. Health Canada License: 80726 In this Video You will Learn: Background information on calprotectin and it’s use in primary care Technical details of calprotectin testing in the laboratory Perspectives and general tips on the use of the BÜHLMANN fCAL® ELISA Contact our team and learn more about
Continue Reading

Connect with BUHLMANN at CDDW 2019!

Canadian Digestive Diseases Week (CDDW) 2019 BUHLMANN Diagnostics Corp Booth: #116 Mar 1 - 3, 2019 | Fairmont Banff Springs Hotel | Banff Alberta Learn More Visit our booth to get an update on our Calprotectin and Therapeutic Drug Monitoring product portfolio: IBDoc®, the ONLY in-vitro diagnostic POC and home testing device to measure the inflammatory marker, fecal
Continue Reading

BUHLMANN Diagnostics Corp Announces New Distribution Agreement with Meridian Biosciences, Inc.

BUHLMANN Diagnostic Corp (BDC), Amherst, NH is proud to announce they have entered into a distribution agreement with Meridian Bioscience, Inc., Cincinnati, Ohio to market the FDA-cleared BÜHLMANN fCAL® ELISA for the quantitative measurement of fecal calprotectin in human stool. The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s
Continue Reading

Two New fCAL turbo Video Testimonials from Portugal

BÜHLMANN fCAL® turbo is for Research Use Only in the US. Not to be used in diagnostic procedures. Health Canada License: 96808 Unilabs Portugal, a private European lab chain, made a comprehensive evaluation of different Calprotectin assays on the market and found many discrepancies with assays from other suppliers. Finally, they chose the BÜHLMANN fCAL® turbo simply because it
Continue Reading

Clinical Trial Combines New Symptom App with IBDoc

Read a recent article from University of Otago on the success of a new smartphone app, IBDSmart, in synergy with BÜHLMANN IBDoc calprotectin home test. Highlight from this Article "The study showed there was no difference in terms of quality of life for patients whether they used the apps or had face-to-face meetings,”  Associate Professor
Continue Reading

LabSense News Fall 2018 Edition

Continue Reading

IBDoc® Talk – Tips and Tricks Teleconference

Health Canada Licence: 98903, Device class: 3  BÜHLMANN IBDoc® is not available for sale in the US. IBDoc® is the first self-testing application for fecal calprotectin in IBD patients that involves three easy steps. IBDoc® allows IBD patients convenient self-testing of fecal calprotectin. Teleconference Overview Goal of Discussion The goal was for Clinical Administrators and Clinical Users from
Continue Reading

BUHLMANN Quantum Blue® fCAL Tutorial

View this demonstration of CALEX® Cap extraction and quantitative fecal calprotectin measurement using the Quantum Blue® fCAL rapid test technology. Quantum Blue® fCAL high range:  Health Canada License: 88674 Quantum Blue® fCAL: Health Canada License: 83477 US: (The Quantum Blue® tests are for Research Use Only. Not for use in diagnostic procedures in the US.) Contact BUHLMANN Today! Contact
Continue Reading

Can mHealth Apps replace clinic visits?

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent article in the Journal of mHealth (Volume 3, Issue 3), McCombie and colleagues performed a systematic review of IBD symptom monitoring smartphone apps. Highlight from this Article In this study, 233 separate apps were found on
Continue Reading

Introducing Patient Home Tests for Calprotectin in a Routine District General Hospital

US: IBDoc® is not available for sale in the US. Health Canada License: 98903, Device class: 3 Read a recent interview with Lead Inflammatory Bowel Disease Nurse, Pearl Avery, conducted by BÜHLMANN's UK distributor Alpha Laboratories: Highlight from this Article “In the six months that we have been working with the IBDoc, one patient was
Continue Reading